- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03964571
Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients (CHEK BAC)
January 30, 2024 updated by: Centre Hospitalier Universitaire de Nīmes
This study will establish whether human and bacterial protease activity can aid therapeutic decision-making, including targeted treatments.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
65
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Catherine Dunyach-Remy
- Phone Number: 04.66.68.32.02
- Email: catherine.dunyach-remy@chu-nimes.fr
Study Locations
-
-
-
Alès, France, 30100
- Recruiting
- CH d'Alès
-
Contact:
- Thibault Fraisse, MD
- Phone Number: 04 66 78 33 33
-
Principal Investigator:
- Thibault Fraisse, MD
-
Bagnols-sur-Cèze, France, 30200
- Recruiting
- CH de Bagnols sur Céze
-
Contact:
- Julien Crouzet
- Phone Number: 04.66.79.78.07
-
Principal Investigator:
- Julien Crouzet, MD
-
Montpellier, France, 34090
- Recruiting
- CHU de Montpellier
-
Contact:
- Ariane Sultan
- Phone Number: 04 67 60 46 50
-
Principal Investigator:
- Ariane Sultan, MD
-
Sub-Investigator:
- Julie Pochic, MD
-
Sub-Investigator:
- Antoine Avignon, MD
-
Nîmes, France, 30029
- Recruiting
- CHU de Nimes
-
Sub-Investigator:
- Catherine Dunyach-Remy, MD
-
Principal Investigator:
- Jean-Philippe Lavigne, MD
-
Sub-Investigator:
- Anne-Marie Guedj, MD
-
Sub-Investigator:
- Olivier Gilly, MD
-
Sub-Investigator:
- Albert Sotto, MD
-
Sub-Investigator:
- Catherine Lechiche, MD
-
Sub-Investigator:
- Elodie Verbeke, MD
-
Sub-Investigator:
- Schuldiner Sophie, MD
-
Contact:
- Anissa Megzari
- Phone Number: 04.66.68.42.36
- Email: drc@chu-nimes.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- The patient has been informed about the study objectives and purpose and their rights as a patient
- The patient is being treated in the Diabetes and Infectious Disease Department
- The patient has a chronic foot and/or heel wound classified as Grade 1-3 according to the Infectious Diseases Society of America.
Exclusion Criteria:
- The subject is participating in another category I interventional study, or has participated in another category I interventional trial in the previous 3 months, or is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- The patient is pregnant or breastfeeding
- The patient has chronic foot and/or heel wound classified as Grade 4 according to the Infectious Diseases Society of America
- Patient with critical ischemia defined by PSGo <50 mmHg or PSCh <70 mmHg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diabetic foot patients
|
fluid swab of wound and measurement of wound onto film
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in size of wound
Time Frame: From Day 0 to week 4
|
% change in surface area of wound; traced on OpSite Flexigrid ® film
|
From Day 0 to week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of elevated protease activity in foot wound
Time Frame: Day 0
|
Binary Yes/No; WOUNDCHEK™ Protease Status
|
Day 0
|
Presence of elevated protease activity in foot wound
Time Frame: Day 14
|
Binary Yes/No; WOUNDCHEK™ Protease Status
|
Day 14
|
Presence of elevated protease activity in foot wound
Time Frame: Day 28
|
Binary Yes/No; WOUNDCHEK™ Protease Status
|
Day 28
|
Presence of bacterial protease activity in foot wound
Time Frame: Day 0, 14 and 28
|
Binary Yes/No; WOUNDCHEK™ Bacterial Status
|
Day 0, 14 and 28
|
Presence of bacterial protease activity in foot wound
Time Frame: Day 14
|
Binary Yes/No; WOUNDCHEK™ Bacterial Status
|
Day 14
|
Presence of bacterial protease activity in foot wound
Time Frame: Day 28
|
Binary Yes/No; WOUNDCHEK™ Bacterial Status
|
Day 28
|
Clinical exam of wound
Time Frame: Day 0
|
Classification as either infection or colonization according to Infectious Diseases Society of America classification
|
Day 0
|
Presence of pathogenic bacteria in wound
Time Frame: Day 0
|
Wound swabs cultured and bacteria identified
|
Day 0
|
Presence of pathogenic bacteria in wound
Time Frame: Day 14
|
Wound swabs cultured and bacteria identified
|
Day 14
|
Presence of pathogenic bacteria in wound
Time Frame: Day 28
|
Wound swabs cultured and bacteria identified
|
Day 28
|
Reduction in size of wound
Time Frame: From Day 0 to Week 2
|
% change in surface area of wound; traced on OpSite Flexigrid ® film
|
From Day 0 to Week 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jean-Philippe Lavigne, CHU Nîmes
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 9, 2019
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
May 24, 2019
First Submitted That Met QC Criteria
May 24, 2019
First Posted (Actual)
May 28, 2019
Study Record Updates
Last Update Posted (Estimated)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Endocrine System Diseases
- Disease Attributes
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Neuropathies
- Foot Ulcer
- Diabetic Foot
- Infections
- Communicable Diseases
- Focal Infection
Other Study ID Numbers
- AOI GCS MERRI/2017/CDR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Infection
-
MicuRxRecruitingDiabetic Foot InfectionSpain, China, United States, Estonia, Latvia, Portugal, Bulgaria, Greece, Italy, Lithuania, Puerto Rico
-
Microbion CorporationCUBRC, MTEC, and US NavyActive, not recruitingDiabetic Foot | Diabetic Foot InfectionUnited States
-
Hospices Civils de LyonCompletedDiabetic Foot InfectionFrance
-
Prisma Health-UpstateTerminated
-
TaiGen Biotechnology Co., Ltd.CompletedDiabetic Foot InfectionsTaiwan, United States, South Africa, Thailand
-
Merck Sharp & Dohme LLCCompletedFoot Infections in Diabetic Patients
-
Balgrist University HospitalRecruitingSurgical Wound | Infection | Antibiotic Side Effect | Diabetic Foot InfectionSwitzerland
-
BioMed Valley Discoveries, IncTerminatedDiabetic Foot InfectionUnited States
-
Dipexium Pharmaceuticals, Inc.CompletedDiabetic Foot InfectionUnited States
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly